Crawford Yongping, Ferrara Napoleone
Genentech, Inc., South San Francisco, California, USA.
Methods Enzymol. 2008;445:125-39. doi: 10.1016/S0076-6879(08)03006-1.
Angiogenesis, the growth of new blood vessels, is required for a variety of normal proliferative processes. Furthermore, it is well established that angiogenesis plays an important role also in neoplastic growth and metastasis. Numerous regulators of angiogenesis have been identified and characterized over the last decades. Among these, vascular endothelial growth factor (VEGF)-A appears especially important in several pathophysiological processes. Several VEGF inhibitors have been approved by the Food and Drug Administration for the treatment of tumors or age-related macular degeneration. This chapter examines the various mouse tumor models in which VEGF inhibitors have been tested and the lessons learned from these studies.
血管生成，即新血管的生长，是多种正常增殖过程所必需的。此外，血管生成在肿瘤生长和转移中也起着重要作用，这一点已得到充分证实。在过去几十年中，已鉴定并表征了许多血管生成调节因子。其中，血管内皮生长因子（VEGF）-A在多个病理生理过程中显得尤为重要。几种VEGF抑制剂已获美国食品药品监督管理局批准用于治疗肿瘤或年龄相关性黄斑变性。本章将探讨已对VEGF抑制剂进行测试的各种小鼠肿瘤模型以及从这些研究中获得的经验教训。
